论文部分内容阅读
选取2015年1月至2015年6月在大连大学附属中山医院内分泌科住院患者47例初发的肥胖2型糖尿病患者,应用利拉鲁肽降糖治疗12周,结果:空腹血糖2小时血糖糖化血红蛋白从体重、腰围Hs-CRP均明显下降肝功能、血脂、尿酸、尿微量蛋白/肌酐治疗前后无明显差异,P>0.05。结论:利拉鲁肽治疗初发肥胖2型糖尿病患者降糖治疗有效,显著降低体重,无低血糖发生。
Forty-seven patients with newly diagnosed type 2 diabetes mellitus admitted to Department of Endocrinology, Zhongshan Hospital Affiliated to Dalian University from January 2015 to June 2015 were selected and treated with liraglutide for 12 weeks. Results: 2-hour fasting plasma glucose Hemoglobin decreased significantly in body weight and waist circumference (Hs-CRP), while there was no significant difference in serum lipid, uric acid and urine microalbumin / creatinine before and after treatment (P> 0.05). CONCLUSION: Liraglutide is effective in reducing hypoglycemia in newly diagnosed obese type 2 diabetic patients, with significant weight loss and no hypoglycemia.